Home

About

Advanced Search

Browse by Discipline

Scientific Societies

E-print Alerts

Add E-prints

E-print Network
FAQHELPSITE MAPCONTACT US


  Advanced Search  

 
302 VOLUME 25 NUMBER 3 MARCH 2007 NATURE BIOTECHNOLOGY and provide strong evidence that targeting the
 

Summary: 302 VOLUME 25 NUMBER 3 MARCH 2007 NATURE BIOTECHNOLOGY
and provide strong evidence that targeting the
Dll4/Notch pathway may lead to exciting new
therapies for clinical investigation.
COMPETING INTERESTS STATEMENT
The author declares that he has no competing
financial interests.
1. Hicklin, D.J. & Ellis, L.M. J. Clin. Oncol. 23, 1011
1027 (2005).
2. Noguera-Troise, I. et al. Nature 444, 10321037
(2006).
3. Ridgway, J. et al. Nature 444, 10831087 (2006).
4. Artavanis-Tsakonas, S., Rand, M.D. & Lake, R.J. Science
284, 770776 (1999).
5. Shutter, J.R. et al. Genes Dev. 14, 13131318
(2000).
6. Gale, N.W. et al. Proc. Natl. Acad. Sci. USA 101,
1594915954 (2004).
7. Krebs, L.T. et al. Genes Dev. 18, 24692473 (2004).
8. Duarte, A. et al. Genes Dev. 18, 24742478 (2004).

  

Source: Ahringe, Julie - Wellcome Trust/Cancer Research UK Gurdon Institute, University of Cambridge
Miska, Eric - Gurdon Institute, University of Cambridge
Miska, Eric - Wellcome Trust/Cancer Research UK Gurdon Institute, University of Cambridge

 

Collections: Biology and Medicine